All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
Randomized, open label Phase 3 study of SAR408701 versus Docetaxel in previously treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
With Unresectable Stage III Non-Small Cell Lung Cancer
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas (NAPOLI 3)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study
of First-line Carboplatin and Paclitaxel in Combination with Durvalumab,
Followed by Maintenance Durvalumab with or without Olaparib in Patients
with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
of First-line Carboplatin and Paclitaxel in Combination with Durvalumab,
Followed by Maintenance Durvalumab with or without Olaparib in Patients
with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST chemo-IO
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just
ipilimumab and nivolumab together. We would also like to find out what effects, good
and bad, that this combination of drugs may have on your cancer. This study will involve
the addition of the FDA approved agent nivolumab to the standard FDA approved
ipilimumab immunotherapy in the hopes that it might further improve the good effects of
the immunotherapy component of the treatment sequence. The combination of
ipilimumab and nivolumab has been shown in recent studies to produce superior
antitumor effects but also more side effects than ipilimumab alone. This combination
has received FDA approval for patients with BRAF V600 wild-type unresectable or
metastatic melanoma. This combination is under review for FDA approval for patients
with BRAF V600 mutant melanoma and is therefore still considered to be experimental
for these patients. GM-CSF is a protein that your body normally produces to signal to
your body to make white blood cells. White blood cells are very important in the body s
defense system as they help identify and destroy foreign invaders, such as bacteria,
viruses, and cells that don t belong, such as cancer cells. Injections of GM-CSF
increase your body s production of white blood cells and also help enhance the function
of the white blood cells. This research study will allow the researchers to know whether
this different approach is better, the same, or worse than the usual approach. To be
better, the study drugs should improve how long you are able to live with your cancer
compared to the usual approach. There will be about 400 people taking part in this
research study, including approximately 15 at this site.
A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
combination with Cisplatin, and to compare it with the standard treatment of Gemcitabine in
combination with Cisplatin in people with biliary tract cancer.
Randomized Double-Blind Phase III Trial Of Vitamin D3 Supplementation In Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-Pd-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Bevacizumab versus observation (not receiving any treatment) on patients with completely
resected or ablated HCC who are at high risk for disease recurrence.
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or
Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)